CalciMedica ने 1-के-5 रिवर्स स्टॉक स्प्लिट लागू किया
- Investing.com
तुलना करने के लिए मीट्रिक्स | CALC | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधCALCपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.4x | −1.5x | −0.3x | |
PEG अनुपात | −0.02 | −0.02 | 0.00 | |
क़ीमत/बुक | 1.5x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 7.2x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 239.6% | 64.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | 4.2% | 9.2% | अनलॉक करें |
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.